Investors Purchase Large Volume of Xenon Pharmaceuticals Call Options (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) was the target of some unusual options trading activity on Wednesday. Investors bought 21,515 call options on the company. This is an increase of 1,415% compared to the typical volume of 1,420 call options.

Analyst Ratings Changes

Several analysts have issued reports on the company. HC Wainwright boosted their price target on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Wedbush decreased their price objective on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday, March 16th. JPMorgan Chase & Co. lifted their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research report on Wednesday, May 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday. Finally, Wells Fargo & Company reissued an “overweight” rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $77.20.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE traded up $6.58 during mid-day trading on Wednesday, reaching $69.95. The company’s stock had a trading volume of 4,750,882 shares, compared to its average volume of 1,381,476. Xenon Pharmaceuticals has a 52 week low of $30.00 and a 52 week high of $70.84. The stock has a fifty day moving average of $55.28 and a two-hundred day moving average of $50.58. The firm has a market capitalization of $6.76 billion, a PE ratio of -14.88 and a beta of 0.61.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.17). During the same period in the prior year, the company posted ($0.83) EPS. Analysts anticipate that Xenon Pharmaceuticals will post -4.92 EPS for the current fiscal year.

Insider Activity at Xenon Pharmaceuticals

In other news, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director owned 24,896 shares of the company’s stock, valued at $1,322,973.44. The trade was a 5.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the sale, the director owned 1,455 shares of the company’s stock, valued at $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.07% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several hedge funds have recently modified their holdings of XENE. JPMorgan Chase & Co. raised its position in shares of Xenon Pharmaceuticals by 11.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock valued at $56,171,000 after buying an additional 142,452 shares in the last quarter. HighVista Strategies LLC grew its position in Xenon Pharmaceuticals by 80.2% in the third quarter. HighVista Strategies LLC now owns 82,190 shares of the biopharmaceutical company’s stock worth $3,300,000 after acquiring an additional 36,570 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in Xenon Pharmaceuticals during the fourth quarter worth approximately $5,342,000. Peregrine Capital Management LLC bought a new stake in Xenon Pharmaceuticals during the fourth quarter worth approximately $7,837,000. Finally, Jain Global LLC purchased a new stake in Xenon Pharmaceuticals during the third quarter valued at approximately $10,133,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.